Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Xanthine oxidoreductase inhibitor"'
Autor:
Yukio Maruyama, Takanori Kumagai, Naoki Sugano, Shigetaka Yoshida, Kimiyoshi Ichida, Shunya Uchida
Publikováno v:
Renal Replacement Therapy, Vol 7, Iss 1, Pp 1-11 (2021)
Abstract Background Whether uric acid (UA)-lowering therapy (ULT) is effective in reducing the progression of renal dysfunction in patients with chronic kidney disease (CKD) remains controversial. Since several advances have been made in therapies fo
Externí odkaz:
https://doaj.org/article/037e06d7105a4f6e8900c9d7ecd61caa
Publikováno v:
Molecular Medicine, Vol 25, Iss 1, Pp 1-13 (2019)
Abstract Background Clinically applied as anti-gout drugs, xanthine oxidoreductase (XOR) inhibitors, especially the potent, selective, non-purine-analog XOR inhibitors febuxostat and topiroxostat, exert organ-protective effects. We tested the hypothe
Externí odkaz:
https://doaj.org/article/f45ce37d13a54e15b566432b41790116
Autor:
Kimiyoshi Ichida, Naoki Sugano, Shigetaka Yoshida, Shunya Uchida, Takanori Kumagai, Yukio Maruyama
Publikováno v:
Renal Replacement Therapy, Vol 7, Iss 1, Pp 1-11 (2021)
Background Whether uric acid (UA)-lowering therapy (ULT) is effective in reducing the progression of renal dysfunction in patients with chronic kidney disease (CKD) remains controversial. Since several advances have been made in therapies for hyperur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::209ff71d61356ea1654f42e7586e4780
https://doaj.org/article/037e06d7105a4f6e8900c9d7ecd61caa
https://doaj.org/article/037e06d7105a4f6e8900c9d7ecd61caa
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hideaki Shimizu, Norimi Ohashi, Masahiko Ando, Tomohiko Naruse, Takanobu Nagata, Toshihiro Mizukoshi, Yosuke Saka, Hiroshi Sobajima, Sawako Kato, Shoichi Maruyama
Publikováno v:
Nephrology. 23(11):1023-1030
Aim: We aimed to evaluate the anti‐albuminuric effects of topiroxostat in Japanese hyperuricaemic patients with diabetic nephropathy. Methods: In this 24‐week, multicentre, open‐label, randomized (1 : 1) trial, we assigned hyperuricaemic patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7cd6806969e3e4166ba4fffc08f1b1b
https://nagoya.repo.nii.ac.jp/records/27083
https://nagoya.repo.nii.ac.jp/records/27083
Autor:
Tomomitsu Sasaki, Ryusuke Sakamoto, Daisuke Okui, Tatsuo Hosoya, Kazutaka Narita, Kenjiro Kimura, Takashi Wada, Daisuke Honda
Publikováno v:
Clinical and Experimental Nephrology. 22(4):860-870
金沢大学医薬保健研究域医学系
Background: Hyperuricemia is supposed to be an independent risk factor for kidney dysfunction in diabetic patients. We attempted to examine the uric acid-lowering effect and the renoprotective effect of
Background: Hyperuricemia is supposed to be an independent risk factor for kidney dysfunction in diabetic patients. We attempted to examine the uric acid-lowering effect and the renoprotective effect of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04387ee6ff3e6fd5b6e0159ec2194d48
http://hdl.handle.net/2297/00050596
http://hdl.handle.net/2297/00050596
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Vascular Health and Risk Management
Several studies suggest that chronic hyperuricemia, the main precursor of gout, is involved in the pathogenesis of different systemic disorders that affect cardiovascular and renal systems, such as hypertension, obesity, hypercholesterolemia, atheros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c305935e453e6bf911fdf49ad5389777
https://doi.org/10.2147/vhrm.s115080
https://doi.org/10.2147/vhrm.s115080
Publikováno v:
Molecular Medicine
Molecular Medicine, Vol 25, Iss 1, Pp 1-13 (2019)
Molecular Medicine, Vol 25, Iss 1, Pp 1-13 (2019)
Background Clinically applied as anti-gout drugs, xanthine oxidoreductase (XOR) inhibitors, especially the potent, selective, non-purine-analog XOR inhibitors febuxostat and topiroxostat, exert organ-protective effects. We tested the hypothesis that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70d4b3ee245cd49c19c35ff08b15816d
https://doi.org/10.1186/s10020-019-0109-y
https://doi.org/10.1186/s10020-019-0109-y
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.